Drug Profile
TAK 816
Alternative Names: CRM-Hib vaccine conjugate - Novartis; Hib-CRM197 vaccine conjugate - Novartis; Monovalent Hib vaccine - Novartis; PRP-CRM197 conjugate Hib vaccine - Novartis; TAK-816; Vaxim HibLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Chiron
- Developer GlaxoSmithKline; GSK
- Class Conjugate vaccines; Haemophilus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilus infections
Most Recent Events
- 09 May 2017 GlaxoSmithKline terminates licensing agreement with Takeda for TAK 816 in Japan
- 22 Jan 2016 Registered for Haemophilus infections (In infants, Prevention) in Japan (IM)
- 01 Mar 2015 Takeda completes a phase III trial for Haemophilus infections (in infants, prevention) in Japan (NCT02074345)